InvestorsHub Logo
Post# of 251706
Next 10
Followers 69
Posts 2711
Boards Moderated 0
Alias Born 02/25/2010

Re: dewophile post# 177546

Monday, 05/05/2014 12:14:21 AM

Monday, May 05, 2014 12:14:21 AM

Post# of 251706
I agree it's difficult to compare across studies, but I still am having a hard time reconciling the data as better than current options. This comes from their(Merrimack) Phase 2 paper.

"Results from one of the largest studies conducted to date for the second-line treatment of APC (CONKO-003) randomised 165 patients to receive a weekly regimen called OFF or 5-FU/folinic acid alone (Pelzer et al, 2008). Patients receiving the oxaliplatin-containing combination demonstrated significantly improved outcomes in terms of both progression-free survival (13 vs 9 weeks, P=0.012) and overall survival (26 vs 13 weeks, P=0.014), leading to the adoption of this regimen (or slight variations thereof) as a de facto standard of care in the salvage setting."

http://www.ejcancer.com/article/S0959-8049(11)00260-7/abstract

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.